| Metastasis from malignant neoplasm of colon and/or rectum
Erbitux vs Stivarga
Side-by-side clinical, coverage, and cost comparison for metastasis from malignant neoplasm of colon and/or rectum.Deep comparison between: Erbitux vs Stivarga with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStivarga has a higher rate of injection site reactions vs Erbitux based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stivarga but not Erbitux, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Erbitux
Stivarga
At A Glance
IV infusion
Weekly or every 2 weeks
EGFR antagonist
Oral
Once daily (21 of 28 days)
Multikinase inhibitor
Indications
- Squamous cell carcinoma of the head and neck
- Metastasis from malignant neoplasm of colon and/or rectum
- Metastasis from malignant neoplasm of colon and/or rectum
- Gastrointestinal Stromal Tumors
- Liver carcinoma
Dosing
Squamous cell carcinoma of the head and neck In combination with radiation therapy: initial 400 mg/m2 IV (120-min) one week prior to radiation, then 250 mg/m2 weekly (60-min) for 6-7 weeks, completing infusion 1 hour prior to radiation; as single-agent or with platinum-based therapy and fluorouracil: weekly (400 mg/m2 initial, 250 mg/m2 subsequent) or biweekly (500 mg/m2 every 2 weeks), completing infusion 1 hour prior to chemotherapy.
Metastasis from malignant neoplasm of colon and/or rectum As single-agent or in combination with irinotecan or FOLFIRI: weekly (400 mg/m2 initial, 250 mg/m2 subsequent) or biweekly (500 mg/m2 every 2 weeks), completing infusion 1 hour prior to irinotecan or FOLFIRI; in combination with encorafenib (BRAF V600E mutation-positive): initial 400 mg/m2 IV (120-min), then 250 mg/m2 weekly (60-min).
Metastasis from malignant neoplasm of colon and/or rectum, Gastrointestinal Stromal Tumors, Liver carcinoma 160 mg orally once daily for the first 21 days of each 28-day cycle, taken after a low-fat meal; continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Cutaneous adverse reactions (rash, pruritus, nail changes), headache, diarrhea, infection; with encorafenib: fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, rash.
Serious Infusion reactions, cardiopulmonary arrest, pulmonary toxicity, dermatologic toxicity (acneiform rash), hypomagnesemia and electrolyte abnormalities, pulmonary embolism.
Postmarketing Aseptic meningitis, mucosal inflammation, Stevens-Johnson syndrome, toxic epidermal necrolysis, life-threatening and fatal bullous mucocutaneous disease.
Most common (>=20%) pain, HFSR/PPES, asthenia/fatigue, diarrhea, decreased appetite/food intake, hypertension, infection, dysphonia, hyperbilirubinemia, fever, mucositis, weight loss, rash, nausea
Serious hepatotoxicity, infections, hemorrhage, gastrointestinal perforation or fistula, dermatological toxicity, hypertension, cardiac ischemia and infarction, reversible posterior leukoencephalopathy syndrome
Postmarketing hypersensitivity reaction, nephrotic syndrome, cardiac failure, arterial aneurysms/dissections/rupture
Pharmacology
EGFR antagonist; cetuximab is a recombinant human/mouse chimeric IgG1 monoclonal antibody that binds specifically to the extracellular domain of EGFR, competitively inhibiting EGF and other ligand binding, blocking receptor-associated kinase phosphorylation, inhibiting cell growth, inducing apoptosis, decreasing matrix metalloproteinase and VEGF production, and mediating antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types.
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in oncogenesis, tumor angiogenesis, metastasis, and tumor immunity, including VEGFR1-3, KIT, PDGFR-alpha/beta, FGFR1/2, RAF-1, BRAF, and CSF1R.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Erbitux
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Stivarga
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Erbitux
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (0/8)
Stivarga
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Erbitux
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Stivarga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Head and Neck Cancer: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Stivarga.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ErbituxView full Erbitux profile
StivargaView full Stivarga profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.